Background: The pathophysiological processes of bipolar disorder (BD) may be detectable by the
INTRODUCTION
Since 1957 when Arvid Carlsson demonstrated that dopamine was a neurotransmitter in the brain (1,2) levels of neurotransmitter precursor and metabolites have been measured in cerebrospinal fluid (CSF) to access central neurochemical function. The pathophysiological processes of several psychiatric disorders may be detectable in CSF. Biomarkers in psychiatric disorders may assist with diagnosis, prediction of disease course, or identification of response outcome to treatments. CSF biomarkers have been proposed in many studies but no CSF biomarkers are integrated into routine clinical practice. Although CSF biomarkers have been investigated in mania and bipolar disorder for more than half century, surprisingly, no exhaustive systematic review has ever been published on CSF biomarkers in BD.
Objectives
We aimed to systematically review studies of CSF biomarkers in patients with bipolar disorder (BD) versus healthy control individuals (HC). Further, we investigated the effect of age, gender, clinical state, medication, technical characteristics of tests, fasting state and, cognitive function if applicable. Finally, risk of bias was systematically assessed.
METHODS

Protocol
A protocol describing methods for the review was prepared and approved by all authors prior to the study. The review is reported according to the PRISMA Statement (3).
Eligibility criteria
Eligible for review were original studies published in English reporting on levels of biological CSF markers in patients ≥ 18 years with diagnosis of BD compared to HC. Studies were excluded if: 1) the groups of patients with BD or the HC group comprised of less than ten 10 individuals, 2) biomarkers were assessed post-mortem, 3) patients had mixed diagnoses and data regarding patients with BD could not be extracted separately, or 4) the smaller study, when more than one publication reported results regarding identical parameters from the same study population.
confounding by appropriate design and/or analytical methods, 5) Statistical methods (excluding confounding) by appropriate use of statistics for primary analysis of effect. Figure 1 presents an overview of the study selection. The electronic database search in PubMed identified 407 titles. Reviews, meta-analyses, editorials or letters were removed after screening of titles and abstracts (n=41). Full text assessments of the remaining 366 papers lead to the exclusion of 332 papers. An additional search in EMBASE supplemented by hand searches (n=3) (9) (10) (11) yielded no further titles to be included. In summary, 34 studies published from 1968-2017 were included in the qualitative synthesis.
RESULTS
Study selection
Cerebrospinal fluid biomarkers
A total of 117 unique biomarkers were investigated in the included studies, see Table 1 . The biomarkers could be categorized into six groups: Monoamine biomarkers (5, (12) (13) (14) (15) (16) (17) (18) , inflammatory biomarkers (19) (20) (21) (22) (23) (24) (25) , hormone biomarkers (13, (26) (27) (28) (29) (30) (31) , neuropeptide biomarkers (4, (13) (14) (15) 18, 19, 24, 29, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) , metabolomics markers (42) , and other biomarkers (29, 43) .
Overall, statistically significant differences (P<0.05) between BD and HC were found for 40 biomarkers and of these eleven biomarkers were evaluated in more than one study. The results were replicated regarding increased homovanillic acid (HVA) (5, 12, 17, 18) and increased 5-hydroxy-indoleacetic acid (5-HIAA) (12, 18) , and both increased and decreased levels were found between BC and HC regarding, 3-methoxy-4-hydroxy-phenylglycol (MHPG) (12, 18) and neural cell adhesion molecule (N-CAM) (19, 25) . No statistically significant differences were found between BD and HC regarding the remaining 77 biomarkers (Table 1) .
Monoamines
Seven monoamine biomarkers were investigated in a total of eight studies including a total of 249 patients with BD and 315 HC (5,12-18) (participants overlap in Sellgren (5) et al and Pålsson et al. (18) ). Increased levels were replicated regarding 5-HIAA (12, 18) and HVA (5, 12, 17, 18) . These studies were characterized by high numbers of participants (17, 18) and subgroup analyses revealed higher concentrations of the biomarker among patients of female gender with mania (12) and a history of psychosis (5, 18) . Divergent results were found regarding MHPG, since an older study found increased MHPG (12) , whereas a recent large study found decreased levels of MHPG (18) .
No statistically significant differences between the BD and HC groups were found in four studies regarding 5-HIAA (13) (14) (15) 17) and in three studies regarding HVA and MHPG (13) (14) (15) . In a recent study, kynurenic acid (KYNA) was increased in a BD subgroup with a history of psychosis (5), but the finding has not yet been replicated.
Overall, data were conflicting due to smaller studies with no clear information regarding age and gender distributions in the samples (13) (14) (15) . One study (17) had a HC group significantly younger than the BD group.
Inflammation
A total of twelve CSF inflammatory biomarkers were investigated in seven studies including a total of 237 patients with BD and 268 HC (19) (20) (21) (22) (23) (24) (25) . Among inflammatory biomarkers only N-CAM was investigated more than once. Thus, N-CAM levels were increased in a small older study with uneven gender distribution (19) and decreased in a large, recent, age and gender-matched study (25) . Highly statistically significant differences were found, but not replicated regarding interleukin (IL)1β, IL6 (21), IL8 (22) , monocytes chemoattractant protein 1 (23) and, chittinase-3-like protein 1 (23) .
No differences between BD and HC were found regarding levels of gamma-globulin (20) , variable alternative sliced exon immune-reactive protein (N-CAM VASE) (24) , IgG (19) , soluble cluster of differentiation 14 (23) , and tissue inhibitor of metallo-protease-1 and 2 (23) .
Hormones
A total of 14 hormone biomarkers were investigated in seven studies including a total of 113 patients with BD and 124 HC (13, (26) (27) (28) (29) (30) (31) . Statistically significant differences between BD and HC were found in three smaller studies regarding cortisol (26) , melatonin (28) , pregnenolone (31), however none of the results were replicated.
None of the remaining biomarkers differentiated the BD from the HC groups: Adrenocorticotrophin (ACTH) (14) , alfa-melanocytes stimulating hormone (14) , atrial natriuretic factor (14) , calcitonin (14) , corticotrophin releasing factor (CRF) (14) , growth hormone (27) , norepinephrine (14) progesterone (31) , thyrotropin-releasing hormone (30) , tyrosine (13) and vasopressin (14) .
Neuropeptides
The results regarding a line of 41 neuropeptide biomarkers were reported in 25 studies including a total of 340 patients with BD and 408 HC (4, (13) (14) (15) 18, 19, 24, 29, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) .Within the group of neuropeptides statistically significant differences between BD and HC were shown regarding cholecystokinin (CCK) and somatostatin. Thus, CCK was investigated in two older and small studies; one study showed decreased levels of CCK (39) and the other study with no information on age and gender distributions, showed no statistically significant differences between the BD and HC groups (38) . Somatostatin was investigated in three smaller, older studies with no information on age and gender. Decreased levels of somatostatin in BD were found in one study (40) and no statistically significant differences between BD and HC were found in two other studies (14, 38) .
Amyloidβ-42 (Aβ-42) was decreased in a small study of late-life BD versus HC (4) . Furthermore, in a large study on younger BD and HC (age range 27-50) no statistically significant differences were found regarding Aβ-42 (32) . A replication of no statistically significant differences between BD and HC was found regarding β-endorphin (14, 34) , GABA (13) (14) (15) , and total CSF protein (19, 24) .
Recent studies have suggested differences between BD and HC regarding amyloid precursor protein α (32), Aβ42/Aβ40 ratio (32), Aβ42/Aβ38 ratio (32), Aβ42/T-tau (4), Aβ 40/P-tau protein (P-tau) ratio (4), glutamine (41) , neurofilament light chain (NF-L) (35) , secretogranin-II (SgII) (33) , and CSF/serum albumin ratio (37) . The results remain to be replicated.
Metabolomics
A recent study of a panel of metabolomics biomarkers in 54 BD males versus 40 HC males (42) found thirteen statistically significantly altered biomarkers: Uric acid, fructose 6-phosphate, ribose 5-phosphate, CoA, 2-oxoisovaleric acid, lactic acid, pyruvic acid, citric acid, isocitric acid, cisaconitic acid, urea, alanine, and tryptophan. After multivariate logistic regression with adjustments for BMI only CSF isocitric acid levels were statistically significantly higher in BD versus HC.
Other
A highly statistically significant difference between ten patients with BD and ten HC was found for sorbitol, but not for glucose (43 
Risk of bias
The following study characteristics were identified to have an effect on the results in one or more studies: 1) study design, 2) sample size of study participants, 3) diagnosis, 4) symptoms, 5) inclusion and exclusion criteria, 6) age, 7) gender, 8) height and weight, 9) medication, 10) smoking, and 11) ethnicity/genetic, 12) statistics, and regarding the biomarkers 13) pre-analytical factors, 14) methods for biomarker analyses.
1) Study design.
The patients were selected from both inpatient (29, 30, 36, 38) and outpatient wards (36) . A possible effect of hospitalization was rejected by Koslow et al. (12) . The included studies were all cross sectional case-control studies. Some authors included follow-up data of subsets of the BD participants in order to reveal effects of medication (17, 27, (29) (30) (31) . Berrettini et al. made an attempt to assess the stability of GHRH over time by repeating CSF GHRH in 11 of 37 HC after a time span of 3 weeks to two years and found a statistically significant correlation between the first and the second lumbar puncture (27) . No other studies reported longitudinal follow-up of the HC group.
Thus, no evidence regarding stability of the biomarkers was given among HC or BD in repeated measures in a larger sample.
2) Sample size.
The size of the study samples ranged from 10 to139 patients with bipolar disorder and 10 to113 healthy control individuals. A majority of the studies were small (<30 BD), though contrasted by the larger cohorts from the St Göran Bipolar Project including 139 patients with BD and 113 HC (5, 18, (21) (22) (23) 32, 35, 41, 42) , the studies by George et al. including 76 patients with BD and 59 HC (29, 31) , and further the recent study by Hidese et al. including 57 patients with BD and 111 HC (25) . Small studies increase the risk of both type 1 and 2 errors. Lack of power may specifically have contributed to no statistically significant differences found in the studies of HVA (13-15), dihydroxy-phenyl-acetic acid (DOPAC) (14) and dopamine sulfate (DPS) (14) .
3) Diagnosis.
In case control studies it is obviously important that the segregation of the groups is strict in order to avoid systematic errors. Diagnosis of bipolar disorder was thorough across the studies: DSM III (19, 24, 30) , DSM IV (4, 5, 15, 18, (21) (22) (23) (24) (25) 28, 30, 32, 33, 35, 37, 41, 42) , specified by Research Diagnostic Criteria (44) (13, 16, 26, (29) (30) (31) 34, 36, 38, 40, 43) . Besides information on BD, demographical information, other clinical parameters as duration of illness, duration of current affective state, smoking have been reported in newer studies and may influence findings.
The healthy control groups were often not described in ways that permit its replication. A line of authors reported that HC were retrieved by newspaper advertisement (12, 15, 25, 29, 31) , among colleges at hospitals (5, 17, 20, 21) , or via national registers (5, 18, (21) (22) (23) 32, 35, 41, 42) . The selection of healthy control individuals for studies of BD is important, since BD often presents with minor psychiatric disorders prior to the onset of the first hypomania or mania. Thus, a healthy control group that includes participants with past minor depressive episodes, isolated episodes of panic disorder, eating disorders, or obsessive compulsive disorder that had remitted spontaneously or with psychotherapy counseling (32) may be problematic and lead to overlooking CSF markers as the HC group may present with deviations in CSF markers similar to those in BD groups.
4) Mood episodes, symptoms and subtypes of BD.
BD patients presented with all types of mood episodes in the included studies. Thus, data could be extracted from the papers regarding patients grouped as mania (12, 13, 16, 17, 20, 26, 34, 38, 40) or as bipolar depressed (15, 39, 40) . Regarding MHPG Koslow et al. found statistically significant differences between patients with mania and HC, but they found no changes between BD as a group and HC (12) . One could suggest that CSF biomarkers differ during mania and depression, but data did not support this. A line of studies investigated patients with either BD type I or type II (5, 19, (21) (22) (23) (24) 28, 29, (31) (32) (33) 35, 37, 41, 42) and different results for the two subtypes were found regarding CSF Neural cell adhesion molecule (N-CAM) levels (19) and secretogranin-II (33) . A number of studies did not specify the subtype of BD (14, 27, 28, 30, 36, 43) , and the St. Göran cohort included a small number of patients with other affective diagnoses including cyclothymia and schizo-affective disorder (5).
When patients are examined in the euthymic state, CSF markers may reflect trait markers (45, 46) , however the definition of euthymia differs across studies. The St. Göran cohort included patients with BD in a euthymic state defined as a scores below 14 on both Montgomery-Åsberg Depression Rating Scale and Young Mania Rating Scale (33) at the date of spinal tap. Berrettini et al. included patients that were euthymic by history and clinical observation for a minimum of four weeks prior to study (36) . Mann et al recruited a group of patients with BD being currently euthymic during the previous month, as assessed by a maximum score of 7 in the 21-item Hamilton Rating Scale for Depression (HAMD), and a maximum score of 4 in the Young Mania Rating Scale (15) .
Regarding monoamines, subgroup analyses of clinical features of the BD revealed that the severity of the disorder (or a factor related to severity) may be important to consider, as the most extreme biomarker levels were found among participants with BD type I (5,12). The effect of specific symptoms was explored by Berettini et al, who found no differences between small subgroups with (n=6) and without (n=20) a history of suicidality in relation to CSF DOPAC, DPS, HVA, MHPG, ACTH, α-melanocyt stimulating hormone, atrial natriuretic factor, calcitonin, CRF, norepinephrine, vasopressin, β-endorphine, β-lipoprotein, calmodulin, GABA, n-terminal fragment of propiomelatonocortin, and neurotensin (14) . Furthermore, psychotic features differentiated participants from those with no psychotic features in various CSF markers including HVA (5) and KYNA (18) . An effect of diagnostic subtype was shown for SG-II (33), thus higher levels were found regarding BD type I compared with to BD type II. George et al. found no correlation between magnesium levels and severity of depression or mania, on the day of the lumbar puncture (29) . In a longitudinal study of nine patients Rubinow et al. showed a statistically significantly lower CSF somatostatin level (P< 0.02) during depressed states compared to those in manic or improved states (40) . Finally, the sAPP-α and β concentrations were negatively associated with co-morbid anxiety (32) . In conclusion symptoms may affect a CSF biomarker.
5) Inclusion and exclusion criteria.
Recent studies clearly reported criteria regarding BD participants, whereas older studies were not that clear, which complicates replication of the results.
6) Age.
Most studies attempted age-and gender matching between BD and HC. However, as can be seen from Table 1 , it was not always possible to extract the precise data. Participants´ ages ranged from below 20 years (17) to 81 years (4). Examples of effects of age were seen, e.g., a statistically significant effect of postmenopausal status in women was shown on CSF MHPG, whereas no effect of age was found in men (12) . Furthermore, CSF magnesium did not change as a function of age (29) . The Aβ42/Aβ38 was negatively associated with age as found by Jakobsson et al. (32) . Thus, age may affect a CSF biomarker.
7) Gender.
Participants were of both genders in all but two papers that included men only (21, 42) . In a line of studies no precise information on gender could be extracted from the papers (5,12- In a total of 15 studies the patients with BD were drug free at the time of the lumbar puncture (12) (13) (14) (15) (16) 24, 26, 27, 29, 31, 34, 36, (38) (39) (40) and statistically significant differences were found regarding cortisol (26) , pregnonolone (31) and, somatostatin (40) . In the remaining 19 studies the patients received medication at the time of the lumbar puncture (4, 5, (17) (18) (19) (20) (21) (22) (23) 25, 28, 30, 32, 33, 35, 37, (41) (42) (43) .
Regarding lithium Berrettini et al. found that lithium treatment was associated with increased CSF 5-HIAA (P=0.05) (47) and no association was seen with GABA (48) . Results from the St Gøran study showed that in patients with BD CSF IL8 (22) , glutamine and D-serine levels were positively associated with lithium treatment (41). Berrettini et al. found no effect of lithium on GHRF levels in 13 patients with BD who provided both a CSF sample on lithium, and a second CSF sample, after a minimum of two weeks off lithium (27) . Further, no statistically significant differences were found in CSF serum/ albumin ratio (37) In order to combine data regarding medicated patients Hidese et al. converted daily doses of antipsychotics to chlorpromazine-equivalent doses and those of antidepressants were converted to imipramine-equivalent doses according to a published guideline for Japanese (25, 49) . Hidese et al. found no statistically significant differences in N-CAM between drug free and medicated patients with BD (25) .
Furthermore, the studies included in this review did not allow an analysis of potential confounding by indication. Patients with BD type I may more often be treated with lithium, divalproate and antipsychotics whereas lamotrigine and antidepressants will be used more extensively in patients with BD type II (50). Poltorak et al. reported that three samples were available from a single patient before and after electroconvulsive therapy (ECT). The CSF concentrations of total N-CAM were decreased by 40% after a course of 16 bilateral treatments (19) . In conclusion, ECT and medication may influence levels of a CSF biomarker.
10) Smoking.
Smoking is often more common in patients groups than among HC (e.g. Jakobsson et al. (33) ) and smoking status has previously been associated with CSF biomarker levels of amino acids in CSF (42), and decreased somatostatin (40) , decreased IL-6, (21), melatonin (28) suggesting that these were not chance findings. However, highly statistically significant findings regarding MHPG were pointing in different directions. Thus, levels of MHPG in BD versus HC were increased in one study (12) and decreased (18) in another.
13) Pre-analytical sampling and storage of CSF.
Most studies report that the biomarkers were collected in the morning under standardized conditions, such as fasting, lateral decubitus or sitting position, storage of CSF at minus 70-80 degrees and authors provided a precise description of the methods used to handle the CSF.
Regarding CSF GHRF Berretini et al. (27) found no evidence of a rostro-caudal gradient as proposed by Gjerris et al. (54) . Few studies gave information of the type of containers used for sampling and storage, e.g. polypropylene tubes (4,14,42) or low protein absorption tubes (25) , types of needles (25) , and whether blood contaminated CSF samples were included (17, 18, 43) . Authors reported blinding of readers of the cerebrospinal fluid marker and the diagnosis of the participants in five studies, only (12, 13, 29, 34, 37) . In most studies it was unclear if the CSF was collected at the same time the diagnosis was given. Bipolar patients may have rapid changes from euthymia to depression or hypomania or mania, thus information regarding the timespan between assessment of the diagnosis and the collection of CSF is important as CSF markers may vary with affective states.
Furthermore, it is unclear in most studies whether data collection was planned prospectively or retrospectively. Finally, no authors gave information on the frequency of side effects following lumbar puncture in the research setting. A precise description of the methods is important when attempts are made to replicate findings.
14) Analytics.
Multiple different methods have been used to analyze biomarkers in the included studies of this review: Protein clusters (55), metabolomics (42), radio-immuno assays (26, 27, 30, 31, 33, 34, 36, 39, 40) , radio receptor assays (RIA) (34), enzyme-linked immunosorbent assays (23, 25, 28, 35) , various immune assays (4, 5, 21, 22, 32, 37, 38) , high performance liquid chromatography (HPLC) (5, 16, 31, 41) , gas chromatographic (GC) mass spectrometric (12, 43) , Western blots (19) . As mentioned previously, increased concentrations of HVA was found in BD compared with HC in three studies. The results were in concert even though they used different Aβ42, P-tau and T-tau protein (Innobia Alz/Bio3 kits) (4, 32) , somatostatin (RIA) (14, 38, 40) , were analyzed by similar techniques, but the results were divergent.
No statistically significant differences were found regarding GABA in three studies using different techniques including Ion-exchange flurometric measurements (13), HPLC (14) , and GC-mass spectrometric (15) . Furthermore, β-endorphines were analyzed with RIA in two studies (14, 34) , and both studies found no statistically significant differences between BD and HC.
CSF markers in relation to blood-based markers
Lumbar puncture is time consuming and the participants may suffer side effects (e.g. headache). If https://www.ncbi.nlm.nih.gov/pubmed/27071153) and plasma/serum NFL would be highly interesting to examine in the context of BD and medications.
Comparisons to other diagnostic groups
A line of the included studies examined biomarkers across diagnostic groups: Schizophrenia Increased levels of the monoamines HVA and 5-HIAA were replicated across studies.
A large proportion of the statistically significant differences in CSF biomarkers between BD and HC derived from 19 studies where the patients received medication for BD whereas only three biomarkers showed statistically significant differences between drug free BD and HC. Medication may influence levels of the biomarker in CSF and it may be a risk of bias along with age, gender, smoking, height, weight, symptoms and diagnoses (BDI/BDII). Further, the stability of biomarkers in BD and HC has not received much attention yet and variation i.e. by season, new episodes and symptom levels are possible risk of bias that could be investigated in longitudinal studies.
When biomarker levels are different between patients with a specific disorder and healthy control individuals in a cross sectional case-control study it is unknown whether the identified biomarker is causing the condition or is a result of the condition, or both. Is the biomarker related to the mood disorder itself or is it a compensatory response to maintain homeostasis with potential therapeutic benefits? These questions can be addressed in longitudinal study designs.
Conclusion
In summary, although cerebrospinal biomarkers in BD versus HC have been investigated during six decades the level of evidence is surprisingly low. The highest level of evidence was reached for the monoamines HVA and 5-HIAA, since data were replicated in different cohorts. Thus, an imbalance of monoamines may relate to the pathology of BD. A total of 77 of the studied CSF biomarkers did not differentiate between BD and HC. Most studies were influenced by risk of bias mainly due to small sample size, lack of data on mood state at the time of lumbar puncture and not considering potential confounders including age, gender, BMI, life style factors such as smoking, and psychotrophic medication.
The available evidence derives largely from case control studies and only some studies supplemented data by follow-up data of subsets of the BD participants that (4, 12, 15, 17, 20, 27, (29) (30) (31) 34, 40, 43) revealed effects of medication and electro convulsive therapy. However, at the moment several groups are investigating different cohorts so future larger longitudinal studies with strict methodology will increase the level of evidence towards revealing the pathology of bipolar disorder that may likely implicate multiple biomarkers. 
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